Skip to content

Author

Jianjin Guo

We have 4 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Bisphenol A and Its Substitutes Bisphenol S/Bisphenol F in Combined Exposure Collectively Exacerbate Hepatotoxicity by Triggering Oxidative Stress and Inflammatory Responses via the PI3K-Akt/NF-κB Axis

Bisphenol A (BPA) and its substitutes bisphenol S (BPS) and bisphenol F (BPF) are environmental endocrine-disrupting chemicals that frequently co-occur. However, the hepatotoxic effects and underlying mechanisms of their combined exposure remain unclear. This study integrated network toxicology, bioinformatics, molec...

Jian-Jin Guo, Shao-Jie Li, Jun-Lei Hao et al. · 0 citations
Jul 2026

Di(2-ethylhexyl) Phthalate (DEHP) Exposure Exacerbates Subarachnoid Hemorrhage by Inducing Astrocyte-Mediated Inflammation and Oxidative Stress through the ADORA1/PI3K-Akt/MAPK Axis.

Di(2-ethylhexyl) phthalate (DEHP) is a widespread plasticizer, but its role in subarachnoid hemorrhage (SAH) remains unclear. Integrating network toxicology, machine learning, transcriptomics, immune infiltration, molecular docking/dynamics, single-cell RNA sequencing, and in vivo/ in vitro experiments, we identified 2...

Shao-Jie Li, Baofang Wu, Jian-Jin Guo et al. · 0 citations
Aug 2026

Integrated network pharmacology, molecular docking, and experimental validation reveal synergistic inhibition of EGFR and PI3K-Akt/JAK2-STAT3 pathways by Esculin and Esculetin to exert anti-colorectal cancer effects.

Colorectal cancer (CRC) remains a global health challenge with limited efficacy of single-target therapies. Esculin and esculetin, the main coumarins of Cortex Fraxini, have been reported to exhibit anti-tumor activities in various cancer cell lines in preclinical studies. This study systematically elucidated the syner...

Lin Liao, Zhao-Hui Tang, P. Luo et al. · 0 citations
Aug 2026

Potential multi-target inhibition of the PI3K-Akt pathway by Fraxetin suppresses colorectal cancer and restores 5-FU sensitivity in 5-FU-resistant CRC cells: An integrated study combining network pharmacology, molecular simulation, and in vitro validation.

It is demonstrated that Fraxetin exerts multi-faceted effects against colorectal cancer, including anti-cancer activity, synergy with chemotherapy, and restoration of 5-FU sensitivity in 5-FU-resistant CRC cells in vitro, through multi-target inhibition of the PI3K-Akt signaling pathway.

Min-Fang Guo, Liang-Dong Zhu, Jian-Jin Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.